Valturna is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 2 US drug patents filed in 2013. Out of these, 1 drug patents are active and 1 has expired. Valturna's patents have been open to challenges since 06 March, 2011. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 03, 2026. Details of Valturna's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8168616 | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
Jul, 2026
(1 year, 1 month from now) | Active |
| US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Valturna's patents.
Latest Legal Activities on Valturna's Patents
Given below is the list of recent legal activities going on the following patents of Valturna.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 03 Jun, 2024 | US8168616 |
| Maintenance Fee Reminder Mailed Critical | 18 Dec, 2023 | US8168616 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Oct, 2019 | US8168616 |
| Post Issue Communication - Certificate of Correction | 23 Jul, 2013 | US8168616 |
| Patent Issue Date Used in PTA Calculation Critical | 01 May, 2012 | US8168616 |
| Recordation of Patent Grant Mailed Critical | 01 May, 2012 | US8168616 |
| Email Notification Critical | 12 Apr, 2012 | US8168616 |
| Issue Notification Mailed Critical | 11 Apr, 2012 | US8168616 |
| Dispatch to FDC | 04 Apr, 2012 | US8168616 |
| Application Is Considered Ready for Issue Critical | 29 Mar, 2012 | US8168616 |
FDA has granted several exclusivities to Valturna. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Valturna, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Valturna.
Exclusivity Information
Valturna holds 2 exclusivities. All of its exclusivities have expired in 2012. Details of Valturna's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Combination(NC) | Sep 16, 2012 |
US patents provide insights into the exclusivity only within the United States, but Valturna is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Valturna's family patents as well as insights into ongoing legal events on those patents.
Valturna's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Valturna's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 03, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Valturna Generics:
There are no approved generic versions for Valturna as of now.
Alternative Brands for Valturna
Valturna which is used for managing high blood pressure., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott |
| |||||||||||||
| Abbvie |
| |||||||||||||
| Adhera |
| |||||||||||||
| Allergan |
| |||||||||||||
| Ani Pharms |
| |||||||||||||
| Azurity |
| |||||||||||||
| Boehringer Ingelheim |
| |||||||||||||
| Cosette |
| |||||||||||||
| Noden Pharma |
| |||||||||||||
| Novartis |
| |||||||||||||
| Upjohn |
| |||||||||||||
| Waylis Therap |
| |||||||||||||
About Valturna
Valturna is a drug owned by Novartis Pharmaceuticals Corp. It is used for managing high blood pressure. Valturna uses Aliskiren Hemifumarate; Valsartan as an active ingredient. Valturna was launched by Novartis in 2009.
Approval Date:
Valturna was approved by FDA for market use on 16 September, 2009.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Valturna is 16 September, 2009, its NCE-1 date is estimated to be 06 March, 2011.
Active Ingredient:
Valturna uses Aliskiren Hemifumarate; Valsartan as the active ingredient. Check out other Drugs and Companies using Aliskiren Hemifumarate; Valsartan ingredient
Treatment:
Valturna is used for managing high blood pressure.
Dosage:
Valturna is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 300MG BASE;320MG | TABLET | Discontinued | ORAL |
| EQ 150MG BASE;160MG | TABLET | Discontinued | ORAL |